Pre-made Cevostamab benchmark antibody ( Bispecific mAb, anti-FCRL5;CD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-103-1mg	1mg	Inquiry
GMP-Bios-ab-103-10mg	10mg	Inquiry
GMP-Bios-ab-103-100mg	100mg	Inquiry
GMP-Bios-ab-103-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody
INN Name	Cevostamab
Target	FCRL5;CD3
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2019
Year Recommended	2020
Companies	Genentech
Conditions Approved	na
Conditions Active	Multiple myeloma
Conditions Discontinued	na
Development Tech	na